Compare · NVO vs TNGX
NVO vs TNGX
Side-by-side comparison of Novo Nordisk A/S (NVO) and Tango Therapeutics Inc. (TNGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TNGX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 40.9x TNGX ($4.47B).
- Over the past year, NVO is down 44.5% and TNGX is up 646.4% - TNGX leads by 690.9 points.
- TNGX has been more active in the news (12 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 18 for TNGX).
- Company
- Novo Nordisk A/S
- Tango Therapeutics Inc.
- Price
- $41.87+2.10%
- $31.14+0.68%
- Market cap
- $183.15B
- $4.47B
- 1M return
- -9.15%
- +34.91%
- 1Y return
- -44.52%
- +646.39%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 8
- 12
- Recent ratings
- 25
- 18
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Tango Therapeutics Inc.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead program is TNG908, a protein arginine methyl transferase 5 inhibitor that is being developed as a treatment for cancers with MTAP deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor that treats cancers with BRCA1 mutations. Tango Therapeutics, Inc. has strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest TNGX
- Director Ketchum John B was granted 4,000 shares, increasing direct ownership by 19% to 24,937 units (SEC Form 4)
- Director Calhoun Lesley Ann was granted 4,000 shares, increasing direct ownership by 32% to 16,500 units (SEC Form 4)
- Director Rothenberg Mace was granted 4,000 shares, increasing direct ownership by 11% to 41,500 units (SEC Form 4)
- Director Lee Sung was granted 570 shares, increasing direct ownership by 3% to 22,870 units (SEC Form 4)
- SEC Form 424B5 filed by Tango Therapeutics Inc.
- Tango Therapeutics Announces Proposed $500 Million Public Offering
- Tango Therapeutics upgraded by Wolfe Research
- Tango Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
- Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)